Life science to outperform, but will remain a niche sector
While supply headwinds have hit life science performance in recent years, long-term fundamentals have been reinforced by the pandemic. We expect a recovery in the short term and strong performance further out, but the sector is likely to remain a relatively small component of real estate portfolios.
Subscriber content
Read this in full, free
Start a free trial and use one of your 10 free starter credits to unlock this piece.
